Berchtold, N. C., Cotman, C. W. (1998). «Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s». Neurobiol. Aging19 (3): 173-189. PMID9661992. doi:10.1016/S0197-4580(98)00052-9.
Waldemar, G., Dubois, B., Emre, M., et al. (enero de 2007). «Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline». Eur J Neurol14 (1): e1-26. PMID17222085. doi:10.1111/j.1468-1331.2006.01605.x.
Mölsä PK, Marttila RJ, Rinne UK (agosto de 1986). «Survival and cause of death in Alzheimer's disease and multi-infarct dementia». Acta Neurol Scand74 (2): 103-107. PMID3776457. doi:10.1111/j.1600-0404.1986.tb04634.x.|fechaacceso= requiere |url= (ayuda)
Berrios G E (1990). «Alzheimer's disease: a conceptual history». Int. J. Ger. Psychiatry5: 355-365. doi:10.1002/gps.930050603.
Boller F, Forbes MM (junio de 1998). «History of dementia and dementia in history: an overview». J. Neurol. Sci.158 (2): 125-133. PMID9702682. doi:10.1016/S0022-510X(98)00128-2.
Bermejo-Pareja F, Benito-León J, Vega S, Medrano MJ, Román GC (enero de 2008). «Incidence and subtypes of dementia in three elderly populations of central Spain». J. Neurol. Sci.264 (1-2): 63-72. PMID17727890. doi:10.1016/j.jns.2007.07.021.
Ferri, CP,; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y.; Jorm, A.; Mathers, C.; Menezes, PR.; Rimmer, E.; Scazufca, M.; Alzheimer's Disease International (diciembre de 2005). «Global prevalence of dementia: a Delphi consensus study»(PDF). The Lancet366 (9503): 2112-2117. PMID16360788. doi:10.1016/S0140-6736(05)67889-0. Archivado desde el original el 25 de junio de 2008. Consultado el 13 de junio de 2008.
Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (agosto de 2003). «Alzheimer disease in the US population: prevalence estimates using the 2000 census». Arch. Neurol.60 (8): 1119-1122. PMID12925369. doi:10.1001/archneur.60.8.1119.
Shen ZX (2004). «Brain cholinesterases: II. The molecular and cellular basis of Alzheimer's disease». Med. Hypotheses63 (2): 308-321. PMID15236795. doi:10.1016/j.mehy.2004.02.031.
Games D, Adams D, Alessandrini R, et al (febrero de 1995). «Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein». Nature373 (6514): 523-527. PMID7845465. doi:10.1038/373523a0.
Holmes C, Boche D, Wilkinson D, et al (julio de 2008). «Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial». Lancet372 (9634): 216-223. PMID18640458. doi:10.1016/S0140-6736(08)61075-2.
Hashimoto M, Rockenstein E, Crews L, Masliah E (2003). «Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases». Neuromolecular Med.4 (1-2): 21-36. PMID14528050. doi:10.1385/NMM:4:1-2:21.
Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J (julio de 2006). «Synapse formation and function is modulated by the amyloid precursor protein». J. Neurosci.26 (27): 7212-7221. PMID16822978. doi:10.1523/JNEUROSCI.1450-06.2006.
Hooper NM (abril de 2005). «Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein». Biochem. Soc. Trans.33 (Pt 2): 335-338. PMID15787600. doi:10.1042/BST0330335.
Ohnishi S, Takano K (marzo de 2004). «Amyloid fibrils from the viewpoint of protein folding». Cell. Mol. Life Sci.61 (5): 511-524. PMID15004691. doi:10.1007/s00018-003-3264-8.
Van Broeck B, Van Broeckhoven C, Kumar-Singh S (2007). «Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches». Neurodegener Dis4 (5): 349-365. PMID17622778. doi:10.1159/000105156.
Chen X, Yan SD (diciembre de 2006). «Mitochondrial Abeta: a potential cause of metabolic dysfunction in Alzheimer's disease». IUBMB Life58 (12): 686-694. PMID17424907. doi:10.1080/15216540601047767.
Greig NH, Mattson MP, Perry T, et al (diciembre de 2004). «New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors,». Ann. N. Y. Acad. Sci.1035: 290-315. PMID15681814. doi:10.1196/annals.1332.018.
Arnáiz E, Almkvist O (2003). «Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease». Acta Neurol. Scand., Suppl.179: 34-41. PMID12603249. doi:10.1034/j.1600-0404.107.s179.7.x.|fechaacceso= requiere |url= (ayuda)
Rapp MA, Reischies FM (2005). «Attention and executive control predict Alzheimer disease in late life: results from the Berlin Aging Study (BASE).». American Journal of Geriatric Psychiatry13 (2): 134-141. PMID15703322. doi:10.1176/appi.ajgp.13.2.134.
Craig D, Mirakhur A, Hart DJ, McIlroy SP, Passmore AP (2005). «A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease». American Journal of Geriatric Psychiatry13 (6): 460-468. PMID15956265. doi:10.1176/appi.ajgp.13.6.460.
Robert PH, Berr C, Volteau M, Bertogliati C, Benoit M, Sarazin M, Legrain S, Dubois B (2006). «Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer's disease: a one-year follow-up study». Clin Neurol Neurosurg108 (8): 733-736. PMID16567037. doi:10.1016/j.clineuro.2006.02.003.
Palmer K, Berger AK, Monastero R, Winblad B, Bäckman L, Fratiglioni L (2007). «Predictors of progression from mild cognitive impairment to Alzheimer disease». Neurology68 (19): 1596-1602. PMID17485646. doi:10.1212/01.wnl.0000260968.92345.3f.
Petersen RC (febrero de 2007). «The current status of mild cognitive impairment--what do we tell our patients?». Nat Clin Pract Neurol3 (2): 60-61. PMID17279076. doi:10.1038/ncpneuro0402.
Jelicic M, Bonebakker AE, Bonke B (1995). «Implicit memory performance of patients with Alzheimer's disease: a brief review». International Psychogeriatrics7 (3): 385-392. PMID8821346. doi:10.1017/S1041610295002134.
Sartori G, Snitz BE, Sorcinelli L, Daum I (septiembre de 2004). «Remote memory in advanced Alzheimer's disease». Arch Clin Neuropsychol19 (6): 779-789. PMID15288331. doi:10.1016/j.acn.2003.09.007.
Síntomas neuropsiquiátricos:
Scarmeas N, Brandt J, Blacker D, et al (diciembre de 2007). «Disruptive behavior as a predictor in Alzheimer disease». Arch. Neurol.64 (12): 1755-1761. PMID18071039. doi:10.1001/archneur.64.12.1755.
Bär M, Kruse A, Re S (diciembre de 2003). «[Situations of emotional significance in residents suffering from dementia]». Z Gerontol Geriatr(en alemán)36 (6): 454-462. PMID14685735. doi:10.1007/s00391-003-0191-0.
Dubois B, Feldman HH, Jacova C, et al (agosto de 2007). «Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria». Lancet Neurol6 (8): 734-746. PMID17616482. doi:10.1016/S1474-4422(07)70178-3.
Clarfield AM (octubre de 2003). «The decreasing prevalence of reversible dementias: an updated meta-analysis». Arch. Intern. Med.163 (18): 2219-2229. PMID14557220. doi:10.1001/archinte.163.18.2219.
Potter GG, Steffens DC (mayo de 2007). «Contribution of depression to cognitive impairment and dementia in older adults». Neurologist13 (3): 105-117. PMID17495754. doi:10.1097/01.nrl.0000252947.15389.a9.
Dougall NJ, Bruggink S, Ebmeier KP (2004). «Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia». Am J Geriatr Psychiatry12 (6): 554-570. PMID15545324. doi:10.1176/appi.ajgp.12.6.554.
Marksteiner J, Hinterhuber H, Humpel C (junio de 2007). «Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein». Drugs Today43 (6): 423-431. PMID17612711. doi:10.1358/dot.2007.43.6.1067341.
Raschetti R, Albanese E, Vanacore N, Maggini M (2007). «Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials». PLoS Med4 (11): e338. PMID18044984. doi:10.1371/journal.pmed.0040338.
Lipton SA (2006). «Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond». Nat Rev Drug Discov5 (2): 160-170. PMID16424917. doi:10.1038/nrd1958.
Ballard C, Waite J (2006). «The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease». Cochrane Database Syst Rev (1): CD003476. PMID16437455. doi:10.1002/14651858.CD003476.pub2.
Bottino CM, Carvalho IA, Alvarez AM, et al (2005). «Cognitive rehabilitation combined with drug treatment in Alzheimer's disease patients: a pilot study». Clin Rehabil19 (8): 861-869. PMID16323385. doi:10.1191/0269215505cr911oa.
Hermans DG, Htay UH, McShane R (2007). «Non-pharmacological interventions for wandering of people with dementia in the domestic setting». Cochrane Database Syst Rev (1): CD005994. PMID17253573. doi:10.1002/14651858.CD005994.pub2.
Woods B, Spector A, Jones C, Orrell M, Davies S (2005). «Reminiscence therapy for dementia». Cochrane Database Syst Rev (2): CD001120. PMID15846613. doi:10.1002/14651858.CD001120.pub2.
Peak JS, Cheston RI (2002). «Using simulated presence therapy with people with dementia». Aging Ment Health6 (1): 77-81. PMID11827626. doi:10.1080/13607860120101095.
Spector A, Orrell M, Davies S, Woods B (2000). «Withdrawn: Reality orientation for dementia». Cochrane Database Syst Rev (3): CD001119. PMID17636652. doi:10.1002/14651858.CD001119.pub2.
Spector A, Thorgrimsen L, Woods B, et al (2003). «Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial». Br J Psychiatry183: 248-254. PMID12948999. doi:10.1192/bjp.183.3.248.
Dunne TE, Neargarder SA, Cipolloni PB, Cronin-Golomb A (2004). «Visual contrast enhances food and liquid intake in advanced Alzheimer's disease». Clinical Nutrition28 (6): 533-538. PMID15297089. doi:10.1016/j.clnu.2003.09.015.
Shega JW, Levin A, Hougham GW, et al (abril de 2003). «Palliative Excellence in Alzheimer Care Efforts (PEACE): a program description». J Palliat Med6 (2): 315-320. PMID12854952. doi:10.1089/109662103764978641.
Gerhard Leinenga, Jürgen Götz (11 de marzo de 2015). «Scanning ultrasound removes amyloid-β and restores memory in an Alzheimer’s disease mouse model». Science Translational Medicine7 (Issue 278): p. 278ra33. doi:10.1126/scitranslmed.aaa2512.|fechaacceso= requiere |url= (ayuda)
Szekely CA, Breitner JC, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, Zandi PP (2008). «NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type». Neurology70 (1): 17-24. PMID18003940. doi:10.1212/01.wnl.0000284596.95156.48.
Craig MC, Murphy DG (2007). «Estrogen: effects on normal brain function and neuropsychiatric disorders». Climacteric. 10 Suppl 2: 97-104. PMID17882683. doi:10.1080/13697130701598746.
Verghese J, Lipton R, Katz M, Hall C, Derby C, Kuslansky G, Ambrose A, Sliwinski M, Buschke H (2003). «Leisure activities and the risk of dementia in the elderly». N Engl J Med348 (25): 2508-2516. PMID12815136. doi:10.1056/NEJMoa022252.
Bennett DA, Schneider JA, Tang Y, Arnold SE, Wilson RS (2006). «The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study». Lancet Neurol5 (5): 406-412. PMID16632311. doi:10.1016/S1474-4422(06)70417-3.
Bialystok E, Craik FIM, Freedman M (2007). «Bilingualism as a protection against the onset of symptoms of dementia». Neuropsychologia42 (2): 459-464. doi:10.1016/j.neuropsychologia.2006.10.009.
Davanipour Z, Tseng CC, Lee PJ, Sobel E (2007). «A case-control study of occupational magnetic field exposure and Alzheimer's disease: results from the California Alzheimer's Disease Diagnosis and Treatment Centers». BMC Neurol7: 13. PMID17559686. doi:10.1186/1471-2377-7-13.
Qiu C, Fratiglioni L, Karp A, Winblad B, Bellander T (2004). «Occupational exposure to electromagnetic fields and risk of Alzheimer's disease». Epidemiology15 (6): 687-694. PMID15475717. doi:10.1097/01.ede.0000142147.49297.9d.
Santibáñez M, Bolumar F, García AM (2007). «Occupational risk factors in Alzheimer's disease: a review assessing the quality of published epidemiological studies». Occupational and Environmental Medicine64 (11): 723-732. PMID17525096. doi:10.1136/oem.2006.028209.
Seidler A, Geller P, Nienhaus A, Bernhardt T, Ruppe I, Eggert S, Hietanen M, Kauppinen T, Frölich L (2007). «Occupational exposure to low frequency magnetic fields and dementia: a case-control study». Occup Environ Med64 (2): 108-114. PMID17043077. doi:10.1136/oem.2005.024190.
Kumar, Anil; Sidhu, Jaskirat; Goyal, Amandeep; Tsao, Jack W. (2021). Alzheimer Disease. StatPearls Publishing. PMID29763097. Consultado el 25 de abril de 2021.
Berchtold, N. C., Cotman, C. W. (1998). «Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s». Neurobiol. Aging19 (3): 173-189. PMID9661992. doi:10.1016/S0197-4580(98)00052-9.
Waldemar, G., Dubois, B., Emre, M., et al. (enero de 2007). «Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline». Eur J Neurol14 (1): e1-26. PMID17222085. doi:10.1111/j.1468-1331.2006.01605.x.
Mölsä PK, Marttila RJ, Rinne UK (agosto de 1986). «Survival and cause of death in Alzheimer's disease and multi-infarct dementia». Acta Neurol Scand74 (2): 103-107. PMID3776457. doi:10.1111/j.1600-0404.1986.tb04634.x.|fechaacceso= requiere |url= (ayuda)
Mölsä PK, Marttila RJ, Rinne UK (marzo de 1995). «Long-term survival and predictors of mortality in Alzheimer's disease and multi-infarct dementia». ActaNeurol Scand91 (3): 159-164. PMID7793228.
Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J (junio de 2004). «The importance of neuritic plaques and tangles to the development and evolution of AD». Neurology62 (11): 1984-1989. PMID15184601.
Alzheimer Alois (1907). «Über eine eigenartige Erikrankung der Hirnrinde [About a peculiar disease of the cerebral cortex]» [Acerca de una peculiar enfermedad de la corteza cerebral.]. Allgemeine Zeitschrift fur Psychiatrie und Psychisch-Gerichtlich Medizin(en alemán)64 (1-2): 146-148.
Alzheimer Alois (1987). «About a peculiar disease of the cerebral cortex. By Alois Alzheimer, 1907 (Translated by L. Jarvik and H. Greenson).». Alzheimer Dis Assoc Disord1 (1): 3-8. PMID3331112.
Boller F, Forbes MM (junio de 1998). «History of dementia and dementia in history: an overview». J. Neurol. Sci.158 (2): 125-133. PMID9702682. doi:10.1016/S0022-510X(98)00128-2.
giancarlo LA, Rocca WA, Schoenberg BS (septiembre de 1986). «Origin of the distinction between Alzheimer's disease and senile dementia: how history can clarify nosolog». Neurology62 (41): 1497-1499. PMID3531918.
Bermejo-Pareja F, Benito-León J, Vega S, Medrano MJ, Román GC (enero de 2008). «Incidence and subtypes of dementia in three elderly populations of central Spain». J. Neurol. Sci.264 (1-2): 63-72. PMID17727890. doi:10.1016/j.jns.2007.07.021.
Andersen K, Launer LJ, Dewey ME, et al (diciembre de 1999). «Gender differences in the incidence of AD and vascular dementia: The EURODEM Studies. EURODEM Incidence Research Group». Neurology53 (9): 1992-1997. PMID10599770.
Ferri, CP,; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y.; Jorm, A.; Mathers, C.; Menezes, PR.; Rimmer, E.; Scazufca, M.; Alzheimer's Disease International (diciembre de 2005). «Global prevalence of dementia: a Delphi consensus study»(PDF). The Lancet366 (9503): 2112-2117. PMID16360788. doi:10.1016/S0140-6736(05)67889-0. Archivado desde el original el 25 de junio de 2008. Consultado el 13 de junio de 2008.
Estimaciones para 2000, Estados Unidos:
Hebert LE, Scherr PA, Bienias JL, Bennett DA, Evans DA (agosto de 2003). «Alzheimer disease in the US population: prevalence estimates using the 2000 census». Arch. Neurol.60 (8): 1119-1122. PMID12925369. doi:10.1001/archneur.60.8.1119.
Shen ZX (2004). «Brain cholinesterases: II. The molecular and cellular basis of Alzheimer's disease». Med. Hypotheses63 (2): 308-321. PMID15236795. doi:10.1016/j.mehy.2004.02.031.
Hardy J, Allsop D (octubre de 1991). «Amyloid deposition as the central event in the aetiology of Alzheimer's disease». Trends Pharmacol. Sci.12 (10): 383-388. PMID1763432.
Polvikoski T, Sulkava R, Haltia M, et al (noviembre de 1995). «Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein». N. Engl. J. Med.333 (19): 1242-1247. PMID7566000.
Ratones trasgénicos:
Games D, Adams D, Alessandrini R, et al (febrero de 1995). «Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein». Nature373 (6514): 523-527. PMID7845465. doi:10.1038/373523a0.
Holmes C, Boche D, Wilkinson D, et al (julio de 2008). «Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial». Lancet372 (9634): 216-223. PMID18640458. doi:10.1016/S0140-6736(08)61075-2.
Goedert M, Spillantini MG, Crowther RA (julio de 1991). «Tau proteins and neurofibrillary degeneration». Brain Pathol.1 (4): 279-286. PMID1669718.
Chun W, Johnson GV (2007). «The role of tau phosphorylation and cleavage in neuronal cell death». Front. Biosci.12: 733-756. PMID17127334.
Alonso R, Pisa D, Rábano A, Carrasco L. «Alzheimer's disease and disseminated mycoses.». Eur J Clin Microbiol Infect Dis. PMID24452965.
Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH (1994). «Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital». Cereb. Cortex4 (2): 138-150. PMID8038565.
Hashimoto M, Rockenstein E, Crews L, Masliah E (2003). «Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases». Neuromolecular Med.4 (1-2): 21-36. PMID14528050. doi:10.1385/NMM:4:1-2:21.
Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J (julio de 2006). «Synapse formation and function is modulated by the amyloid precursor protein». J. Neurosci.26 (27): 7212-7221. PMID16822978. doi:10.1523/JNEUROSCI.1450-06.2006.
Turner PR, O'Connor K, Tate WP, Abraham WC (mayo de 2003). «Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory». Prog. Neurobiol.70 (1): 1-32. PMID12927332.
Hooper NM (abril de 2005). «Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein». Biochem. Soc. Trans.33 (Pt 2): 335-338. PMID15787600. doi:10.1042/BST0330335.
Ohnishi S, Takano K (marzo de 2004). «Amyloid fibrils from the viewpoint of protein folding». Cell. Mol. Life Sci.61 (5): 511-524. PMID15004691. doi:10.1007/s00018-003-3264-8.
Van Broeck B, Van Broeckhoven C, Kumar-Singh S (2007). «Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches». Neurodegener Dis4 (5): 349-365. PMID17622778. doi:10.1159/000105156.
Yankner BA, Duffy LK, Kirschner DA (octubre de 1990). «Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides». Science (journal).250 (4978): 279-282. PMID2218531.
Chen X, Yan SD (diciembre de 2006). «Mitochondrial Abeta: a potential cause of metabolic dysfunction in Alzheimer's disease». IUBMB Life58 (12): 686-694. PMID17424907. doi:10.1080/15216540601047767.
Greig NH, Mattson MP, Perry T, et al (diciembre de 2004). «New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors,». Ann. N. Y. Acad. Sci.1035: 290-315. PMID15681814. doi:10.1196/annals.1332.018.
Seripa D, Matera MG, Franceschi M, et al (julio de 2008). «The RELN locus in Alzheimer's disease». J Alzheimers Dis.14 (3): 335-344. PMID18599960.
Preclinicos:
Linn RT, Wolf PA, Bachman DL, et al (mayo de 1995). «The 'preclinical phase' of probable Alzheimer's disease. A 13-year prospective study of the Framingham cohort». Arch. Neurol.52 (5): 485-490. PMID7733843.|fechaacceso= requiere |url= (ayuda)
Arnáiz E, Almkvist O (2003). «Neuropsychological features of mild cognitive impairment and preclinical Alzheimer's disease». Acta Neurol. Scand., Suppl.179: 34-41. PMID12603249. doi:10.1034/j.1600-0404.107.s179.7.x.|fechaacceso= requiere |url= (ayuda)
Rapp MA, Reischies FM (2005). «Attention and executive control predict Alzheimer disease in late life: results from the Berlin Aging Study (BASE).». American Journal of Geriatric Psychiatry13 (2): 134-141. PMID15703322. doi:10.1176/appi.ajgp.13.2.134.
Spaan PE, Raaijmakers JG, Jonker C (2003). «Alzheimer's disease versus normal ageing: a review of the efficiency of clinical and experimental memory measures». Journal of Clinical Experimental Neuropsychology25 (2): 216-233. PMID12754679.
Craig D, Mirakhur A, Hart DJ, McIlroy SP, Passmore AP (2005). «A cross-sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease». American Journal of Geriatric Psychiatry13 (6): 460-468. PMID15956265. doi:10.1176/appi.ajgp.13.6.460.
Robert PH, Berr C, Volteau M, Bertogliati C, Benoit M, Sarazin M, Legrain S, Dubois B (2006). «Apathy in patients with mild cognitive impairment and the risk of developing dementia of Alzheimer's disease: a one-year follow-up study». Clin Neurol Neurosurg108 (8): 733-736. PMID16567037. doi:10.1016/j.clineuro.2006.02.003.
Palmer K, Berger AK, Monastero R, Winblad B, Bäckman L, Fratiglioni L (2007). «Predictors of progression from mild cognitive impairment to Alzheimer disease». Neurology68 (19): 1596-1602. PMID17485646. doi:10.1212/01.wnl.0000260968.92345.3f.
Petersen RC (febrero de 2007). «The current status of mild cognitive impairment--what do we tell our patients?». Nat Clin Pract Neurol3 (2): 60-61. PMID17279076. doi:10.1038/ncpneuro0402.
Förstl H, Kurz A (1999). «Clinical features of Alzheimer's disease». European Archives of Psychiatry and Clinical Neuroscience249 (6): 288-290. PMID10653284.
Carlesimo GA, Oscar-Berman M (junio de 1992). «Memory deficits in Alzheimer's patients: a comprehensive review». Neuropsychol Rev3 (2): 119-169. PMID1300219.
Jelicic M, Bonebakker AE, Bonke B (1995). «Implicit memory performance of patients with Alzheimer's disease: a brief review». International Psychogeriatrics7 (3): 385-392. PMID8821346. doi:10.1017/S1041610295002134.
Galasko D, Schmitt F, Thomas R, Jin S, Bennett D (2005). «Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease». Journal of the International Neuropsychology Society11 (4): 446-453. PMID16209425.
Galasko D, Schmitt F, Thomas R, Jin S, Bennett D (julio de 2005). «Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease». J Int Neuropsychol Soc11 (4): 446-453. PMID16209425.
Sartori G, Snitz BE, Sorcinelli L, Daum I (septiembre de 2004). «Remote memory in advanced Alzheimer's disease». Arch Clin Neuropsychol19 (6): 779-789. PMID15288331. doi:10.1016/j.acn.2003.09.007.
Scarmeas N, Brandt J, Blacker D, et al (diciembre de 2007). «Disruptive behavior as a predictor in Alzheimer disease». Arch. Neurol.64 (12): 1755-1761. PMID18071039. doi:10.1001/archneur.64.12.1755.
Honig LS, Mayeux R (junio de 2001). «Natural history of Alzheimer's disease». Aging (Milano).13 (3): 171-182. PMID11442300.
Bär M, Kruse A, Re S (diciembre de 2003). «[Situations of emotional significance in residents suffering from dementia]». Z Gerontol Geriatr(en alemán)36 (6): 454-462. PMID14685735. doi:10.1007/s00391-003-0191-0.
Mendez MF (2006). «The accurate diagnosis of early-onset dementia». International Journal of Psychiatry Medicine36 (4): 401-412. PMID17407994.
Dubois B, Feldman HH, Jacova C, et al (agosto de 2007). «Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria». Lancet Neurol6 (8): 734-746. PMID17616482. doi:10.1016/S1474-4422(07)70178-3.
Blacker D, Albert MS, Bassett SS, Go RC, Harrell LE, Folstein MF (diciembre de 1994). «Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. The National Institute of Mental Health Genetics Initiative». Arch. Neurol.51 (12): 1198-1204. PMID7986174.
Ito N (mayo de 1996). «[Clinical aspects of dementia]». Hokkaido Igaku Zasshi(en japonés)71 (3): 315-320. PMID8752526.
Tombaugh TN, McIntyre NJ (septiembre de 1992). «The mini-mental state examination: a comprehensive review». J Am Geriatr Soc40 (9): 922-935. PMID1512391.
Pasquier F (enero de 1999). «Early diagnosis of dementia: neuropsychology». J. Neurol.246 (1): 6-15. PMID9987708.
Harvey PD, Moriarty PJ, Kleinman L, et al (2005). «The validation of a caregiver assessment of dementia: the Dementia Severity Scale». Alzheimer Dis Assoc Disord19 (4): 186-194. PMID16327345.
Antoine C, Antoine P, Guermonprez P, Frigard B (2004). «[Awareness of deficits and anosognosia in Alzheimer's disease.]». Encephale(en francés)30 (6): 570-577. PMID15738860.
Cruz VT, Pais J, Teixeira A, Nunes B (2004). «[The initial symptoms of Alzheimer disease: caregiver perception]». Acta Med Port(en portugués)17 (6): 435-444. PMID16197855.
Clarfield AM (octubre de 2003). «The decreasing prevalence of reversible dementias: an updated meta-analysis». Arch. Intern. Med.163 (18): 2219-2229. PMID14557220. doi:10.1001/archinte.163.18.2219.
Geldmacher DS, Whitehouse PJ (mayo de 1997). «Differential diagnosis of Alzheimer's disease». Neurology48 (5 Suppl 6): S2-9. PMID9153154.
Potter GG, Steffens DC (mayo de 2007). «Contribution of depression to cognitive impairment and dementia in older adults». Neurologist13 (3): 105-117. PMID17495754. doi:10.1097/01.nrl.0000252947.15389.a9.
Dougall NJ, Bruggink S, Ebmeier KP (2004). «Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia». Am J Geriatr Psychiatry12 (6): 554-570. PMID15545324. doi:10.1176/appi.ajgp.12.6.554.
Marksteiner J, Hinterhuber H, Humpel C (junio de 2007). «Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein». Drugs Today43 (6): 423-431. PMID17612711. doi:10.1358/dot.2007.43.6.1067341.
Geula C, Mesulam MM (1995). «Cholinesterases and the pathology of Alzheimer disease». Alzheimer Dis Assoc Disord. 9 Suppl 2: 23-28. PMID8534419.
Stahl SM (2000). «The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action». J Clin Psychiatry61 (11): 813-814. PMID11105732.
Raschetti R, Albanese E, Vanacore N, Maggini M (2007). «Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials». PLoS Med4 (11): e338. PMID18044984. doi:10.1371/journal.pmed.0040338.
Lipton SA (2006). «Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond». Nat Rev Drug Discov5 (2): 160-170. PMID16424917. doi:10.1038/nrd1958.
Raina P, Santaguida P, Ismaila A, et al (2008). «Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline». Annals of Internal Medicine148 (5): 379-397. PMID18316756.
Uso de antipsicóticos:
Ballard C, Waite J (2006). «The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease». Cochrane Database Syst Rev (1): CD003476. PMID16437455. doi:10.1002/14651858.CD003476.pub2.
Bottino CM, Carvalho IA, Alvarez AM, et al (2005). «Cognitive rehabilitation combined with drug treatment in Alzheimer's disease patients: a pilot study». Clin Rehabil19 (8): 861-869. PMID16323385. doi:10.1191/0269215505cr911oa.
Doody RS, Stevens JC, Beck C, et al (2001). «Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology». Neurology56 (9): 1154-1166. PMID11342679.
Hermans DG, Htay UH, McShane R (2007). «Non-pharmacological interventions for wandering of people with dementia in the domestic setting». Cochrane Database Syst Rev (1): CD005994. PMID17253573. doi:10.1002/14651858.CD005994.pub2.
Woods B, Spector A, Jones C, Orrell M, Davies S (2005). «Reminiscence therapy for dementia». Cochrane Database Syst Rev (2): CD001120. PMID15846613. doi:10.1002/14651858.CD001120.pub2.
Peak JS, Cheston RI (2002). «Using simulated presence therapy with people with dementia». Aging Ment Health6 (1): 77-81. PMID11827626. doi:10.1080/13607860120101095.
Spector A, Orrell M, Davies S, Woods B (2000). «Withdrawn: Reality orientation for dementia». Cochrane Database Syst Rev (3): CD001119. PMID17636652. doi:10.1002/14651858.CD001119.pub2.
Spector A, Thorgrimsen L, Woods B, et al (2003). «Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial». Br J Psychiatry183: 248-254. PMID12948999. doi:10.1192/bjp.183.3.248.
Head B (enero de 2003). «Palliative care for persons with dementia». Home Healthc Nurse21 (1): 53-60; quiz 61. PMID12544465.
Shega JW, Levin A, Hougham GW, et al (abril de 2003). «Palliative Excellence in Alzheimer Care Efforts (PEACE): a program description». J Palliat Med6 (2): 315-320. PMID12854952. doi:10.1089/109662103764978641.
No hay pruebas que recomienden medidas preventivas:
Kawas CH (2006). «Medications and diet: protective factors for AD?». Alzheimer Dis Assoc Disord20 (3 Suppl 2): S89-96. PMID16917203.
Szekely CA, Breitner JC, Fitzpatrick AL, Rea TD, Psaty BM, Kuller LH, Zandi PP (2008). «NSAID use and dementia risk in the Cardiovascular Health Study: role of APOE and NSAID type». Neurology70 (1): 17-24. PMID18003940. doi:10.1212/01.wnl.0000284596.95156.48.
Craig MC, Murphy DG (2007). «Estrogen: effects on normal brain function and neuropsychiatric disorders». Climacteric. 10 Suppl 2: 97-104. PMID17882683. doi:10.1080/13697130701598746.
Mori K, Takeda M (2007). «Hormone replacement Up-to-date. Hormone replacement therapy and brain function». Clin Calcium(en japonés)17 (9): 1349-1354. PMID17767023.
Verghese J, Lipton R, Katz M, Hall C, Derby C, Kuslansky G, Ambrose A, Sliwinski M, Buschke H (2003). «Leisure activities and the risk of dementia in the elderly». N Engl J Med348 (25): 2508-2516. PMID12815136. doi:10.1056/NEJMoa022252.
Bennett DA, Schneider JA, Tang Y, Arnold SE, Wilson RS (2006). «The effect of social networks on the relation between Alzheimer's disease pathology and level of cognitive function in old people: a longitudinal cohort study». Lancet Neurol5 (5): 406-412. PMID16632311. doi:10.1016/S1474-4422(06)70417-3.
Davanipour Z, Tseng CC, Lee PJ, Sobel E (2007). «A case-control study of occupational magnetic field exposure and Alzheimer's disease: results from the California Alzheimer's Disease Diagnosis and Treatment Centers». BMC Neurol7: 13. PMID17559686. doi:10.1186/1471-2377-7-13.
Qiu C, Fratiglioni L, Karp A, Winblad B, Bellander T (2004). «Occupational exposure to electromagnetic fields and risk of Alzheimer's disease». Epidemiology15 (6): 687-694. PMID15475717. doi:10.1097/01.ede.0000142147.49297.9d.
Shcherbatykh I, Carpenter DO (mayo de 2007). «The role of metals in the etiology of Alzheimer's disease». J. Alzheimers Dis.11 (2): 191-205. PMID17522444.
Kukull WA, Larson EB, Bowen JD, et al (junio de 1995). «Solvent exposure as a risk factor for Alzheimer's disease: a case-control study». Am. J. Epidemiol.141 (11): 1059-1071; discusión: 1072-1079. PMID7771442.
Santibáñez M, Bolumar F, García AM (2007). «Occupational risk factors in Alzheimer's disease: a review assessing the quality of published epidemiological studies». Occupational and Environmental Medicine64 (11): 723-732. PMID17525096. doi:10.1136/oem.2006.028209.
Seidler A, Geller P, Nienhaus A, Bernhardt T, Ruppe I, Eggert S, Hietanen M, Kauppinen T, Frölich L (2007). «Occupational exposure to low frequency magnetic fields and dementia: a case-control study». Occup Environ Med64 (2): 108-114. PMID17043077. doi:10.1136/oem.2005.024190.
Rondeau V (2002). «A review of epidemiologic studies on aluminum and silica in relation to Alzheimer's disease and associated disorders». Rev Environ Health17 (2): 107-121. PMID12222737.|fechaacceso= requiere |url= (ayuda)
Martyn CN, Coggon DN, Inskip H, Lacey RF, Young WF (mayo de 1997). «Aluminum concentrations in drinking water and risk of Alzheimer's disease». Epidemiology8 (3): 281-286. PMID9115023.
Ferri, CP,; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y.; Jorm, A.; Mathers, C.; Menezes, PR.; Rimmer, E.; Scazufca, M.; Alzheimer's Disease International (diciembre de 2005). «Global prevalence of dementia: a Delphi consensus study»(PDF). The Lancet366 (9503): 2112-2117. PMID16360788. doi:10.1016/S0140-6736(05)67889-0. Archivado desde el original el 25 de junio de 2008. Consultado el 13 de junio de 2008.
scielo.br
FERREIRA, Pricilla Costa, PIAI, Kamila de Almeida, TAKAYANAGUI, Angela Maria Magosso et al. Aluminum as a risk factor for Alzheimer's disease. Rev. Latino-Am. Enfermagem [online]. 2008, vol. 16, n.º 1 [citado 2008-09-10], pp. 151-157. Disponible en la World Wide Web: [1]. ISSN 0104-1169. doi: 10.1590/S0104-11692008000100023
MARTINS, Sergilaine Pereira and DAMASCENO, Benito Pereira. Prospective and retrospective memory in mild Alzheimer's disease. Arq. Neuro-Psiquiatr. [online]. 2008, vol. 66, no. 2b [Consultado el 10 de septiembre de 2008], pp. 318-322. Disponible en la World Wide Web: [2]. ISSN 0004-282X. doi: 10.1590/S0004-282X2008000300006
Ferri, CP,; Prince, M.; Brayne, C.; Brodaty, H.; Fratiglioni, L.; Ganguli, M.; Hall, K.; Hasegawa, K.; Hendrie, H.; Huang, Y.; Jorm, A.; Mathers, C.; Menezes, PR.; Rimmer, E.; Scazufca, M.; Alzheimer's Disease International (diciembre de 2005). «Global prevalence of dementia: a Delphi consensus study»(PDF). The Lancet366 (9503): 2112-2117. PMID16360788. doi:10.1016/S0140-6736(05)67889-0. Archivado desde el original el 25 de junio de 2008. Consultado el 13 de junio de 2008.
